Topic

Onivyde (irinotecan liposome)

A collection of 33 issues

Aetna (CVS Health) Coverage Criteria for Onivyde (Irinotecan Liposome) in North Carolina: What Counts as "Medically Necessary"?

Answer Box: Getting Onivyde Covered by Aetna (CVS Health) in North Carolina Aetna requires prior authorization for Onivyde (irinotecan liposome) with strict medical necessity criteria. You must have metastatic pancreatic adenocarcinoma, ECOG performance status 0-1, adequate biliary drainage, and documented failure of gemcitabine-based therapy. Submit PA via Aetna's
6 min read

Work With Your Doctor to Get Onivyde (Irinotecan Liposome) Approved by Cigna in New Jersey

Answer Box: Getting Onivyde Covered by Cigna in New Jersey Cigna requires prior authorization for Onivyde (irinotecan liposome) with strict medical necessity criteria. Your oncologist must document metastatic pancreatic adenocarcinoma, ECOG performance status 0-1, adequate organ function, and either first-line NALIRIFOX eligibility or progression on prior gemcitabine therapy. Submit through
7 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Aetna CVS Health in Washington: Forms, Appeals, and Step-by-Step Approval Guide

Answer Box: Getting Onivyde Covered by Aetna CVS Health in Washington Quick Path to Approval: Onivyde (irinotecan liposome) requires prior authorization from Aetna CVS Health for metastatic pancreatic adenocarcinoma. Your oncologist must document ECOG performance status 0-1, adequate biliary drainage, and prior gemcitabine-based therapy failure. Submit the Aetna prior authorization
6 min read

Work With Your Doctor to Get Onivyde (Irinotecan Liposome) Approved by UnitedHealthcare in North Carolina: PA Requirements, Appeals, and Provider Scripts

Quick Answer: Getting Onivyde Approved in North Carolina UnitedHealthcare requires prior authorization for Onivyde (irinotecan liposome) with step therapy requirements. The fastest path: work with your oncologist to submit comprehensive PA documentation showing ECOG 0-1 status, adequate organ function, and either first-line NALIRIFOX eligibility or progression after gemcitabine-based therapy. If
6 min read

Renewing Onivyde (Irinotecan Liposome) Approval with Blue Cross Blue Shield in Virginia: Annual Review Requirements and Timeline

Answer Box: Renewing Your Onivyde Coverage Anthem Blue Cross Blue Shield Virginia requires annual prior authorization renewal for Onivyde (irinotecan liposome). Start the renewal process 30-45 days before your current authorization expires to avoid treatment interruptions. Your oncologist must submit updated clinical documentation through Availity Essentials showing continued medical necessity,
6 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Cigna in Pennsylvania: Forms, Appeals & Approval Process

Answer Box: Fastest Path to Onivyde Coverage Onivyde (irinotecan liposome) requires prior authorization from Cigna in Pennsylvania. Your oncologist must submit clinical documentation showing metastatic pancreatic adenocarcinoma, progression on gemcitabine-based therapy, and adequate organ function (ECOG 0-1). The drug is typically covered on Cigna formularies but with strict medical necessity
5 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Humana in Ohio: Complete Coding, Prior Authorization, and Appeals Guide

Quick Answer: Getting Onivyde Covered by Humana in Ohio Onivyde (irinotecan liposome) requires prior authorization from Humana for all regimens. The fastest path: ensure your oncologist submits complete documentation with correct ICD-10 codes (C25.0-C25.9 for pancreatic cancer), HCPCS code J9205, and medical necessity justification referencing FDA approval for
6 min read